Parkside Financial Bank & Trust’s Summit Therapeutics SMMT Stock Holding History

Parkside Financial Bank & Trust’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$816	Buy	56 +36	+180%	+$638	﹤0.01%	2474
2026 Q1	$380	Buy	+20	New	+$323	﹤0.01%	2598
2025 Q4	–	Sell	-18	Closed	-$372	–	2790
2025 Q3	$372	Buy	+18	New	+$437	﹤0.01%	2619
2025 Q2	–	Sell	-55	Closed	-$1.06K	–	2976
2025 Q1	$1.06K	Buy	+55	New	+$1.1K	﹤0.01%	2083
2020 Q2	–	Sell	-398	Closed	-$1K	–	1673
2020 Q1	$1K	Hold	398	–	–	﹤0.01%	1327
2019 Q4	$1K	Hold	398	–	–	﹤0.01%	1468
2019 Q3	$1K	Hold	398	–	–	﹤0.01%	1443
2019 Q2	$1K	Hold	398	–	–	﹤0.01%	1449
2019 Q1	$1K	Hold	398	–	–	﹤0.01%	1410
2018 Q4	$0	Buy	+398	New	+$619	﹤0.01%	1562

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Parkside Financial Bank & Trust's SMMT Position: Q2 2026 in Review

Parkside Financial Bank & Trust increased its Summit Therapeutics (SMMT) stake by 180% in Q2 2026, buying an estimated $638 and bringing the position to 56 shares worth $816. The position accounts for ﹤0.01% of the portfolio, ranked #2474.

Parkside Financial Bank & Trust first reported a position in SMMT in Q4 2018 and has held it in 10 quarters since. The position peaked at $1.06K in Q1 2025. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

Parkside Financial Bank & Trust held 56 shares of Summit Therapeutics worth $816 as of Q2 2026.
Parkside Financial Bank & Trust bought 36 Summit Therapeutics shares in Q2 2026, an estimated $638.
Summit Therapeutics made up ﹤0.01% of Parkside Financial Bank & Trust's portfolio in Q2 2026, its #2474 holding.
Parkside Financial Bank & Trust first reported a position in Summit Therapeutics in Q4 2018 and has held it in 10 quarters since.
Parkside Financial Bank & Trust's Summit Therapeutics position peaked at $1.06K in Q1 2025.
242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Parkside Financial Bank & Trust's 13F filing for Q2 2026, filed 4 Sep 2026.